Targeting cancer associated fibroblasts to enhance immunotherapy: emerging strategies and future perspectives

Christopher J. Hanley; Gareth J. Thomas

doi:10.18632/oncotarget.27936

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Targeting cancer associated fibroblasts to enhance immunotherapy: emerging strategies and future perspectives

Christopher J. Hanley and Gareth J. Thomas _

PDF | Full Text | How to cite

Oncotarget. 2021; 12:1427-1433. https://doi.org/10.18632/oncotarget.27936

Metrics: PDF 1441 views | Full Text 2880 views | ?

Abstract

Christopher J. Hanley1 and Gareth J. Thomas1^,2

1 School of Cancer Sciences, University of Southampton, Southampton, UK

2 Cancer Research UK and NIHR Southampton Experimental Cancer Medicine Centre, Southampton, UK

Correspondence to:

Gareth J. Thomas,

email:

[email protected]

Keywords: tumour microenvironment; cancer associated fibroblasts; immunotherapy

Received: March 23, 2021 Accepted: March 24, 2021 Published: July 06, 2021

Copyright: © 2021 Hanley and Thomas. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Cancer associated fibroblasts are a prominent component of the tumour microenvironment in most solid cancers. This heterogeneous population of cells are known to play an important role in tumour progression and recent studies have demonstrated that CAFs may confer resistance to checkpoint immunotherapy, suggesting that targeting these cells could improve response rates. However, effective clinical strategies for CAF targeting have yet to be identified. In this editorial, we highlight current limitations in our understanding of CAF heterogeneity, and discuss the potential and possible approaches for CAF-directed therapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27936

Publication Alerts

Research Perspectives:

Targeting cancer associated fibroblasts to enhance immunotherapy: emerging strategies and future perspectives

Abstract